AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2028366 — intervention group
Group type: COMPARATOR
Intervention: 7-day tetracycline regimen
Number of subjects: 918
Study 7081179 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilatation and antireflux surgery (Group I, 20 patients)
Number of subjects: 38
Study 7081179 — intervention group
Group type: COMPARATOR
Intervention: Dilatation plus medical management (Group II, 18 patients)
Number of subjects: 38
Study 31899379 — intervention group
Group type: EXPERIMENTAL
Intervention: Photoactivated disinfection (PAD)
Number of subjects: 25
Study 31899379 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvadora persica (SP) gel application
Number of subjects: 25
Study 31899379 — intervention group
Group type: COMPARATOR
Intervention: Professionally administered plaque removal (PAPR)
Number of subjects: 25
Study 31270101 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco Heating System 2.2 (THS)
Number of subjects: 984
Study 31270101 — intervention group
Group type: COMPARATOR
Intervention: Continued smoking of preferred cigarette brand
Number of subjects: 984
Study 28317086 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Support Psychotherapy (GSP)
Number of subjects: 0
Study 28317086 — intervention group
Group type: COMPARATOR
Intervention: Group HIV education
Number of subjects: 0
Study 26159015 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingfei Decoction (QD) treatment group
Number of subjects: 48
Study 24631099 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated reminder messages for vaccine doses two and three
Number of subjects: 365
Study 24631099 — intervention group
Group type: COMPARATOR
Intervention: Routine follow-up (control)
Number of subjects: 365
Study 23066765 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge Preparation Program (DPP)
Number of subjects: 49
Study 23066765 — intervention group
Group type: COMPARATOR
Intervention: Usual rehabilitation program (Control)
Number of subjects: 49
Study 19776405 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalated dose of daunorubicin (90 mg/m²) plus cytarabine (200 mg/m² for 7 days)
Number of subjects: 813
Study 19776405 — intervention group
Group type: COMPARATOR
Intervention: Conventional dose of daunorubicin (45 mg/m²) plus cytarabine (200 mg/m² for 7 days)
Number of subjects: 813
Study 17096464 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy
Number of subjects: 67
Study 17096464 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical case management
Number of subjects: 67
Study 17096464 — intervention group
Group type: EXPERIMENTAL
Intervention: Both cognitive-behavioral group therapy and clinical case management
Number of subjects: 67
Study 16793780 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-min break
Number of subjects: 30
Study 16793780 — intervention group
Group type: COMPARATOR
Intervention: No break (Control)
Number of subjects: 30
Study 12631177 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel matrix proteins (EMP) treatment
Number of subjects: 20
Study 12631177 — intervention group
Group type: COMPARATOR
Intervention: Conventional flap debridement with ICI
Number of subjects: 20
Study 12631177 — intervention group
Group type: COMPARATOR
Intervention: Conventional flap debridement with RBI
Number of subjects: 20
Study 12631177 — intervention group
Group type: COMPARATOR
Intervention: Conventional flap debridement (both ICI and RBI)
Number of subjects: 20
Study 11085964 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine (intra-arterial infusion)
Number of subjects: 8
Study 11085964 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside (exogenous nitric oxide donor)
Number of subjects: 8
Study 11085964 — intervention group
Group type: COMPARATOR
Intervention: Verapamil (calcium channel blocker)
Number of subjects: 8
Study 11085964 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin (sublingual administration)
Number of subjects: 8
Study 8857879 — intervention group
Group type: EXPERIMENTAL
Intervention: Indwelling percutaneous intramuscular electrode composed of helically coiled Teflon‐coated rope stranded from 19 hard drawn wires of SUS 316L stainless steel (SES 114)
Number of subjects: 17
Study 8857879 — intervention group
Group type: EXPERIMENTAL
Intervention: Indwelling percutaneous intramuscular electrode
Number of subjects: 17
Study 1352732 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (2 or 3 mg.kg-1)
Number of subjects: 27
Study 1352732 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (3 mg.kg-1)
Number of subjects: 27
Study 1352732 — intervention group
Group type: COMPARATOR
Intervention: Esmolol and topical laryngeal anaesthesia
Number of subjects: 27
Study 6144933 — intervention group
Group type: EXPERIMENTAL
Intervention: Screened with modern mammography
Number of subjects: 30000
Study 6144933 — intervention group
Group type: COMPARATOR
Intervention: Not screened (unscreened subjects)
Number of subjects: 30000
Study 30361250 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 25‐100 mg (titrated upwards over 9 days)
Number of subjects: 223
Study 30361250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223
Study 30361250 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 223
Study 30361250 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline and Placebo
Number of subjects: 223
Study 28916591 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-guided glucose infusion rate (GIR) with continuous glucose monitoring (CGM)
Number of subjects: 50
Study 25792176 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 1 mg/kg
Number of subjects: 30
Study 25792176 — intervention group
Group type: COMPARATOR
Intervention: Magnesium 30 mg/kg
Number of subjects: 30
Study 23385272 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection
Number of subjects: 165
Study 23385272 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 165
Study 23385272 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection plus physiotherapy
Number of subjects: 165
Study 23385272 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection plus physiotherapy
Number of subjects: 165
Study 23385272 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 165
Study 23385272 — intervention group
Group type: COMPARATOR
Intervention: No physiotherapy
Number of subjects: 165
Study 21300192 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care
Number of subjects: 175
Study 21300192 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 175
Study 19483418 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced dose of docetaxel (40 or 50 mg/m²)
Number of subjects: 0
Study 19483418 — intervention group
Group type: COMPARATOR
Intervention: Standard dose of docetaxel (60 mg/m²)
Number of subjects: 0
Study 17089233 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam 8 mg i.v. at the end of the operation followed by 8 mg b.i.d., i.v. for 24 hours
Number of subjects: 40
Study 17089233 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam
Number of subjects: 40
Study 15041568 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 34
Study 15041568 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone
Number of subjects: 34
Study 15041568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 11719730 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg oral gemfibrozil twice daily for 2 days
Number of subjects: 10
Study 11719730 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg oral gemfibrozil
Number of subjects: 10
Study 11719730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9322139 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (FK506)
Number of subjects: 15
Study 8432299 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 6.25 mg every 6 h on the first day and 12.5 mg qid on the second day if MAP > or = 70 mmHg (group 1)
Number of subjects: 36
Study 8432299 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group 2)
Number of subjects: 36
Study 3829592 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified single breath method for estimation of cardiac output
Number of subjects: 100
Study 30617247 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative hypersensitive C-reactive protein (hs-CRP) levels
Number of subjects: 1132
Study 30617247 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative homocysteine (HCY) levels
Number of subjects: 1132
Study 30617247 — intervention group
Group type: EXPERIMENTAL
Intervention: History of diabetes
Number of subjects: 1132
Study 30617247 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary bifurcation lesions
Number of subjects: 1132
Study 30617247 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent length
Number of subjects: 1132
Study 28699550 — intervention group
Group type: EXPERIMENTAL
Intervention: Community engagement intervention
Number of subjects: 12312
Study 28699550 — intervention group
Group type: COMPARATOR
Intervention: Control clusters
Number of subjects: 12312
Study 26044829 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 97
Study 26044829 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 97
Study 22738092 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 81
Study 22738092 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin (PHT)
Number of subjects: 81
Study 22738092 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous-plus-oral regimen (LEV)
Number of subjects: 81
Study 22738092 — intervention group
Group type: COMPARATOR
Intervention: Total intravenous-plus-oral regimen (PHT)
Number of subjects: 81
Study 21705281 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 7.5 or 15 mg/kg intravenously (I.V.) on day 1, every 21 days plus investigator's choice of agents (pemetrexed, docetaxel, or erlotinib) for second-line and subsequent lines of treatment.
Number of subjects: 0
Study 21705281 — intervention group
Group type: COMPARATOR
Intervention: Investigator's choice of agents alone indicated for use in second-line and subsequent lines of treatment, but no further bevacizumab treatment.
Number of subjects: 0
Study 18562414 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (selective serotonin reuptake inhibitor)
Number of subjects: 20
Study 16406721 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolised hyaluronic acid (HA)
Number of subjects: 14
Study 16406721 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 14
Study 14640845 — intervention group
Group type: EXPERIMENTAL
Intervention: Central words (personally significant items)
Number of subjects: 0
Study 14640845 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral words (task-relevant items)
Number of subjects: 0
Study 14640845 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral words (personally significant items)
Number of subjects: 0
Study 12922956 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy including glucocorticoids
Number of subjects: 0
Study 12922956 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine alone (COBRA trial)
Number of subjects: 0
Study 12922956 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (2001 cohort with early RA)
Number of subjects: 0
Study 12922956 — intervention group
Group type: EXPERIMENTAL
Intervention: Active disease
Number of subjects: 0
Study 12922956 — intervention group
Group type: EXPERIMENTAL
Intervention: Remission
Number of subjects: 0
Study 10689835 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40
Study 10689835 — intervention group
Group type: COMPARATOR
Intervention: Control (droperidol and fentanyl)
Number of subjects: 40
Study 8638787 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 60 mg IV 15 min after skin incision
Number of subjects: 30
Study 8638787 — intervention group
Group type: COMPARATOR
Intervention: Placebo IV
Number of subjects: 30
Study 1999742 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice only
Number of subjects: 1286
Study 1999742 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief patient-centered counseling
Number of subjects: 1286
Study 1999742 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling plus prescription of nicotine-containing gum (Nicorette)
Number of subjects: 1286
Study 1999742 — intervention group
Group type: COMPARATOR
Intervention: Telephone counseling
Number of subjects: 1286
Study 6234279 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 40
Study 6234279 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin
Number of subjects: 40
Study 31504608 — intervention group
Group type: COMPARATOR
Intervention: No supplemental VE (CON)
Number of subjects: 204
Study 31504608 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 IU/kg dry matter (LOW)
Number of subjects: 204
Study 31504608 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 IU per steer daily (MED)
Number of subjects: 204
Study 31504608 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 IU per steer daily (HIGH)
Number of subjects: 204
Study 30133134 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnamyl Isobutyrate (CIB) 0.45 mg in 75 g glucose solution
Number of subjects: 26
Study 30133134 — intervention group
Group type: COMPARATOR
Intervention: Control (75 g glucose solution)
Number of subjects: 26
Study 26740346 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-hour group structured education programme with annual refresher course and regular phone contact
Number of subjects: 880
Study 26740346 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 880
Study 25129333 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarkers analyzed using a point‐of‐care device in the ambulance
Number of subjects: 480
Study 25129333 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 480
Study 23185753 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuzheng Jianpi Decoction (FJD) combined with chemotherapy
Number of subjects: 167
Study 20605898 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise combined with caloric restriction (EX + CR); caloric restriction of 20-35% below baseline energy requirements, supervised training sessions 4 times per week, 30-60 min at moderate intensity
Number of subjects: 33
Study 20605898 — intervention group
Group type: COMPARATOR
Intervention: Light conditioning (LC); eucaloric diet, supervised training sessions 2 times per week, 30-60 min at moderate intensity
Number of subjects: 33
Study 18019991 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowles pinning
Number of subjects: 62
Study 18019991 — intervention group
Group type: COMPARATOR
Intervention: Plating
Number of subjects: 62
Study 16261956 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized budesonide (1 mg/dose)
Number of subjects: 26
Study 16261956 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nebulized saline)
Number of subjects: 26
Study 12297711 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal balloon endometrial ablation therapy
Number of subjects: 26
Study 12297711 — intervention group
Group type: COMPARATOR
Intervention: Gestagen therapy
Number of subjects: 26
Study 10225243 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking-cessation intervention (12 intensive sessions with behavior modification and nicotine chewing gum)
Number of subjects: 5887
Study 10225243 — intervention group
Group type: COMPARATOR
Intervention: Usual-care group (advised to stop smoking)
Number of subjects: 5887
Study 10225243 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention groups (smoking cessation)
Number of subjects: 5887
Study 10225243 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous smokers
Number of subjects: 5887
Study 10225243 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained quitters
Number of subjects: 5887
Study 10225243 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 5887
Study 10225243 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory symptoms
Number of subjects: 5887
Study 7602060 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha 2a (IFN-alpha 2a) at an induction dose of 6 MIU thrice weekly for 3 months, followed by 3 MIU thrice weekly for an additional 3 months as maintenance therapy.
Number of subjects: 1831
Study 7602060 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha 2a (IFN-alpha 2a)
Number of subjects: 1831
Study 1693732 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine ER 5 mg
Number of subjects: 251
Study 1693732 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine ER 10 mg
Number of subjects: 251
Study 1693732 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine ER 20 mg
Number of subjects: 251
Study 1693732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study 227340 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting fluphenazine decanoate with social therapy (ST)
Number of subjects: 105
Study 227340 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting fluphenazine decanoate
Number of subjects: 105
Study 227340 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fluphenazine hydrochloride
Number of subjects: 105
Study 227340 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 105
Study 28760696 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation training (4 sessions over 12 months)
Number of subjects: 157
Study 28760696 — intervention group
Group type: COMPARATOR
Intervention: Control (status quo, no training)
Number of subjects: 157
Study 26406319 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory training group
Number of subjects: 31
Study 26406319 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 31
Study 23446733 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based exercise (WE)
Number of subjects: 14
Study 23446733 — intervention group
Group type: COMPARATOR
Intervention: Land-based exercise (LE)
Number of subjects: 14
Study 21504540 — intervention group
Group type: EXPERIMENTAL
Intervention: BioAggregate (BA)
Number of subjects: 28
Study 21504540 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA-A)
Number of subjects: 28
Study 21504540 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA-PR)
Number of subjects: 28
Study 21504540 — intervention group
Group type: COMPARATOR
Intervention: Calcium Hydroxide (CH)
Number of subjects: 28
Study 18070199 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral neuromodulation (SNM)
Number of subjects: 111
Study 16825841 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai-Chi exercise
Number of subjects: 50
Study 16825841 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic exercise
Number of subjects: 50
Study 16825841 — intervention group
Group type: COMPARATOR
Intervention: Self-help program
Number of subjects: 50
Study 12766742 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular pacing (BiV)
Number of subjects: 33
Study 12766742 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular pacing (RV)
Number of subjects: 33
Study 12766742 — intervention group
Group type: COMPARATOR
Intervention: No pacing
Number of subjects: 33
Study 11417777 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 94
Study 11417777 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine chewing gum
Number of subjects: 94
Study 11417777 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch
Number of subjects: 94
Study 11417777 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal nicotine spray
Number of subjects: 94
Study 11417777 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nicotine
Number of subjects: 94
Study 11417777 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine sublingual tablet
Number of subjects: 94
Study 11417777 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-mg gum
Number of subjects: 94
Study 11417777 — intervention group
Group type: COMPARATOR
Intervention: Bupropion
Number of subjects: 94
Study 9327189 — intervention group
Group type: EXPERIMENTAL
Intervention: soluble aspirin
Number of subjects: 12
Study 9327189 — intervention group
Group type: COMPARATOR
Intervention: plain aspirin
Number of subjects: 12
Study 9327189 — intervention group
Group type: COMPARATOR
Intervention: enteric-coated aspirin granules
Number of subjects: 12
Study 9327189 — intervention group
Group type: COMPARATOR
Intervention: mouth-dispersible aspirin
Number of subjects: 12
Study 7942531 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine abusers in group 1 (rehabilitation)
Number of subjects: 200
Study 7942531 — intervention group
Group type: COMPARATOR
Intervention: Cocaine abusers in group 2 (emergency room)
Number of subjects: 200
Study 7942531 — intervention group
Group type: COMPARATOR
Intervention: Cocaine abusers in group 3 (sudden death)
Number of subjects: 200
Study 3259087 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 1 mg/kg intravenous bolus for induction and 0.1 mg/kg/minute continuous infusion for maintenance
Number of subjects: 16
Study 3259087 — intervention group
Group type: COMPARATOR
Intervention: Ketamine 1.5 mg/kg intravenous bolus for induction and 50 micrograms/kg/minute continuous infusion for maintenance
Number of subjects: 16
Study 1908080 — intervention group
Group type: COMPARATOR
Intervention: Nicotine gum at $20/box
Number of subjects: 106
Study 1908080 — intervention group
Group type: COMPARATOR
Intervention: Nicotine gum at $6/box
Number of subjects: 106
Study 1908080 — intervention group
Group type: COMPARATOR
Intervention: Nicotine gum at $0/box
Number of subjects: 106
Study 1908080 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum (all price groups)
Number of subjects: 106
Study 22297 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol administered before bronchoscopy
Number of subjects: 60
Study 22297 — intervention group
Group type: COMPARATOR
Intervention: Local anesthesia
Number of subjects: 60
Study 22297 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 60
Study 31885286 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon monoxide islets (islets harvested in a carbon monoxide-saturated medium)
Number of subjects: 0